News About: Pharm. Affairs
SK acquires approval of first ‘Vimpat’ generic, next-generation epilepsy therapy
SK Chemicals acquired a permit to commercialize the first generic of ‘Vimpat Tab(lacosamide)’ that is known as a next-generation epilepsy therapy.
According to the industry on the 1st, SK Chemicals acquired approval ...
Xarelto’s firm top position and Eliquis’s first 2nd in ranking
The launch of a next-generation novel oral anticoagulant(NOAC) ‘Eliquis(generic name: apixaban)’ attracted attention of the industry as becoming the top 2 prescription product for the first time in the quarter. ‘Xarel...
Monthly schizophrenia therapy ‘Abilify Maintena’ launched with insurance benefit
A schizophrenia therapy whose patient drug compliance and recurrence control were improved compared to oral drugs, ‘Abilify Maintena’ will be launched this September.
Korea Otsuka Pharmaceuticals(CEO Seung-ho Moon) ...
Series of Bupropion generic approvals
Is it because of a great advance of an antismoking treatment which recorded KRW 4.2 billion prescriptions last year, Nicopion(generic name: bupropion, Hanmi Pharm)? Multiple pharmaceutical companies attracted attentio...
Celltrion’s Remsima occupies 40% of original drug market in Europe
The number of European patients who were prescribed the Celltrion’s biosimilar antibody Remsima was observed to exceed approximately 105 thousand people as of the 2nd quarter this year.
According to Celltrion, Remsim...
G-CSF injections extended in insurance benefits, increasing cancer patient cure rates
As a part of the ‘Top 4 Severe Disease Coverage Extension Plan,’ the Ministry of Health and Welfare(Ministry Jin-yup Jung) is going to drastically extend application of the health insurance benefit from the 1st of Sep...
Super antibacterial ‘Tygacil’ continues to monopolization, succeeding in defending patent
The domestic exclusive license of a Pfizer’s super antibacterial drug ‘Tygacil(tigecycline)’ is expected to be extended.
The substance patent of Tygacil was expired this May, but the company has blocked other generic...
Bayer’s hemophilia therapy ‘Kogenate’ voluntarily returned in Korea
Bayer Korea will voluntarily collect back its hemophilia A therapy, Kogenate FS Inj.
It will be a follow-up action to prevent a quality issue since the company encountered disapproval of its products manufactured in ...
Domestic companies will have delay on launching blockbuster ‘Trajenta’ generics
Domestic generic companies failed in challenging the substance patent of antidiabetic ‘Trajenta.’
In the past, domestic companies won nullification suits for its crystalline and formulation patents which are expiring...
“Remote medicine dispenser must require enough demo projects before implemented”
An opinion of the National Assembly Research Service was proposed that enough demo projects must precede before actively implementing remote medicine dispensers.
On the 29th, the National Assembly Research Service pu...
